Skip to main content
Top
Published in: Heart and Vessels 3/2013

01-05-2013 | Short Communication

Eicosapentaenoic acid suppresses adverse effects of C-reactive protein overexpression on pressure overload-induced cardiac remodeling

Authors: Toshiyuki Nagai, Toshihisa Anzai, Yoshinori Mano, Hidehiro Kaneko, Atsushi Anzai, Yasuo Sugano, Yuichiro Maekawa, Toshiyuki Takahashi, Tsutomu Yoshikawa, Keiichi Fukuda

Published in: Heart and Vessels | Issue 3/2013

Login to get access

Abstract

Serum C-reactive protein (CRP) elevation is associated with poor clinical outcome in patients with heart failure (HF). We previously reported that CRP exacerbates the development of pressure overload-induced cardiac remodeling through an enhanced inflammatory response and oxidative stress. In the present study, we examined the effect of eicosapentaenoic acid (EPA), a suppressor of inflammatory response and oxidative stress, on pressure overload-induced cardiac remodeling. Transverse aortic constriction (TAC) was performed on transgenic mice overexpressing CRP (CRPtg) and nontransgenic littermates (TAC/CON). CRPtg with TAC operation were randomly assigned to be fed a standard diet (TAC/CRPtg) or an EPA-enriched diet (7 % of total energy) (TAC/CRPtg/EPA). Myocardial mRNA level of transforming growth factor-β1, proinflammatory cytokines, and oxidative stress markers were increased in TAC/CRPtg in comparison with TAC/CON 1 and 4 weeks after the operation. These parameters were significantly suppressed in TAC/CRPtg/EPA compared with TAC/CRPtg. In addition, after 4 weeks of EPA treatment, as compared with TAC/CRPtg, TAC/CRPtg/EPA mice demonstrated reduced heart and lung weights, increased left ventricular fractional shortening, and decreased left ventricular end-diastolic pressure, together with decreased cardiac hypertrophy, fibrosis, and improved cardiac function. In conclusion, the anti-inflammatory and antioxidative properties of EPA may make it an effective therapeutic strategy for adverse cardiac remodeling associated with CRP overexpression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S (1997) C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 96:778–784PubMedCrossRef Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S (1997) C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 96:778–784PubMedCrossRef
2.
go back to reference Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, Mitamura H, Ogawa S (2003) Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction—role of neurohormones and cytokines. Int J Cardiol 88:257–265PubMedCrossRef Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, Mitamura H, Ogawa S (2003) Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction—role of neurohormones and cytokines. Int J Cardiol 88:257–265PubMedCrossRef
3.
go back to reference Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, Witteman JC (2006) C-reactive protein and risk of heart failure. The Rotterdam study. Am Heart J 152:514–520PubMedCrossRef Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, Witteman JC (2006) C-reactive protein and risk of heart failure. The Rotterdam study. Am Heart J 152:514–520PubMedCrossRef
4.
go back to reference Araujo JP, Lourenco P, Azevedo A, Frioes F, Rocha-Goncalves F, Ferreira A, Bettencourt P (2009) Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 15:256–266PubMedCrossRef Araujo JP, Lourenco P, Azevedo A, Frioes F, Rocha-Goncalves F, Ferreira A, Bettencourt P (2009) Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 15:256–266PubMedCrossRef
5.
go back to reference Verma S, Devaraj S, Jialal I (2006) Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 113:2135–2150PubMed Verma S, Devaraj S, Jialal I (2006) Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 113:2135–2150PubMed
6.
go back to reference Nagai T, Anzai T, Kaneko H, Mano Y, Anzai A, Maekawa Y, Takahashi T, Meguro T, Yoshikawa T, Fukuda K (2011) C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension 57:208–215PubMedCrossRef Nagai T, Anzai T, Kaneko H, Mano Y, Anzai A, Maekawa Y, Takahashi T, Meguro T, Yoshikawa T, Fukuda K (2011) C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension 57:208–215PubMedCrossRef
7.
go back to reference Duda MK, O’Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, Chess DJ, Azimzadeh AM, Harris WS, Sharov VG, Sabbah HN, Stanley WC (2009) Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 81:319–327PubMedCrossRef Duda MK, O’Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, Chess DJ, Azimzadeh AM, Harris WS, Sharov VG, Sabbah HN, Stanley WC (2009) Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 81:319–327PubMedCrossRef
8.
go back to reference Lennie TA, Chung ML, Habash DL, Moser DK (2005) Dietary fat intake and proinflammatory cytokine levels in patients with heart failure. J Card Fail 11:613–618PubMedCrossRef Lennie TA, Chung ML, Habash DL, Moser DK (2005) Dietary fat intake and proinflammatory cytokine levels in patients with heart failure. J Card Fail 11:613–618PubMedCrossRef
9.
go back to reference Kurisu S, Ishibashi K, Kato Y, Mitsuba N, Dohi Y, Nishioka K, Kihara Y (2011) Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Heart Vessels. doi:10.1007/s00380-011-0213-6 Kurisu S, Ishibashi K, Kato Y, Mitsuba N, Dohi Y, Nishioka K, Kihara Y (2011) Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Heart Vessels. doi:10.​1007/​s00380-011-0213-6
10.
go back to reference Ueda M, Doumei T, Takaya Y, Ohnishi N, Takaishi A, Hirohata S, Miyoshi T, Shinohata R, Usui S, Kusachi S (2011) Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction. Heart Vessels 26:145–152CrossRef Ueda M, Doumei T, Takaya Y, Ohnishi N, Takaishi A, Hirohata S, Miyoshi T, Shinohata R, Usui S, Kusachi S (2011) Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction. Heart Vessels 26:145–152CrossRef
11.
go back to reference Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1223–1230PubMedCrossRef Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1223–1230PubMedCrossRef
12.
go back to reference Duda MK, O’Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC (2007) Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 76:303–310PubMedCrossRef Duda MK, O’Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC (2007) Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 76:303–310PubMedCrossRef
13.
go back to reference Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45:2015–2021PubMedCrossRef Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45:2015–2021PubMedCrossRef
14.
go back to reference Duda MK, O’Shea KM, Stanley WC (2009) Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res 84:33–41PubMedCrossRef Duda MK, O’Shea KM, Stanley WC (2009) Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res 84:33–41PubMedCrossRef
15.
go back to reference Dobaczewski M, Chen W, Frangogiannis NG (2011) Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 51:600–606PubMedCrossRef Dobaczewski M, Chen W, Frangogiannis NG (2011) Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 51:600–606PubMedCrossRef
16.
go back to reference Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, Szalai AJ, Wong BC, Lau CP, Lan HY (2010) C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 55:953–960PubMedCrossRef Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, Szalai AJ, Wong BC, Lau CP, Lan HY (2010) C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 55:953–960PubMedCrossRef
17.
go back to reference Shimojo N, Jesmin S, Zaedi S, Maeda S, Soma M, Aonuma K, Yamaguchi I, Miyauchi T (2006) Eicosapentaenoic acid prevents endothelin-1-induced cardiomyocyte hypertrophy in vitro through the suppression of TGF-beta 1 and phosphorylated JNK. Am J Physiol Heart Circ Physiol 291:H835–845 Shimojo N, Jesmin S, Zaedi S, Maeda S, Soma M, Aonuma K, Yamaguchi I, Miyauchi T (2006) Eicosapentaenoic acid prevents endothelin-1-induced cardiomyocyte hypertrophy in vitro through the suppression of TGF-beta 1 and phosphorylated JNK. Am J Physiol Heart Circ Physiol 291:H835–845
Metadata
Title
Eicosapentaenoic acid suppresses adverse effects of C-reactive protein overexpression on pressure overload-induced cardiac remodeling
Authors
Toshiyuki Nagai
Toshihisa Anzai
Yoshinori Mano
Hidehiro Kaneko
Atsushi Anzai
Yasuo Sugano
Yuichiro Maekawa
Toshiyuki Takahashi
Tsutomu Yoshikawa
Keiichi Fukuda
Publication date
01-05-2013
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 3/2013
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-012-0270-5

Other articles of this Issue 3/2013

Heart and Vessels 3/2013 Go to the issue